Read & React
Quick links
Latest comments
-
Pakrit Jittapiromsak – June 18, 2013
“Since she was GCS 14, I would do the same with limitation in amount of procedure time and contras...” -
Balveer Chandrawat – June 12, 2013
“Can this results be better by putting 2 overlapping self ex intracranial stent instead of puttin...” -
Rohen Harrichandparsad – June 11, 2013
“I would consider open surgical clipping as a good option for this patient.” -
Balveer Chandrawat – June 11, 2013
“ST works some times and it is really a good technique to avoid exchange menuver which is difficul...” -
Michael Holt – June 10, 2013
“Thank you Pr. Cognard et. al. I might be misreading, but Drs Bacelar and Katsaridis have suggeste...”
ITGI obtains CE Mark for cranial stents
ITGI CEO Israel Schreiber said that the new stent can be a good alternative for treating aneurysms. The company's share price soared 66% on the news.
ITGI Medical Ltd (You will be visiting a website outside of LINNConline, we are not responsible for its contents). has obtained EU CE Mark for its latest version of its pericardium covered stent - the AneuGraftNx. ITGI's share price rose 66% on the announcement to NIS 0.118, giving a market cap of NIS 13 million.
The AneuGraftNx stent is designed for specific neurological indications, including endovascular treatment of intracranial aneurysms, carotid cavernous fistuals, and intracranial dissections. ITGI will continue to collate clinical data on the new stents, which have been found to be safe and effective in previous trials, ahead of the commercial launch in a few months.
The new stent is partially covered by living tissue, which enables precise treatment of the damaged artery, greatly reducing the risk of blockages.
ITGI CEO Israel Schreiber said that the new stent can be a good alternative for treating aneurysms, because it can fully and immediately isolate the area of the aneurysm, in contrast to current treatments, which require 6-12 months to do so, and only with a 70-80% chance of success. He added that the new stents could open new joint ventures for the company in neurology.
